This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial (RESET)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeshi Morimoto, Kyoto University, Graduate School of Medicine
ClinicalTrials.gov Identifier:
NCT01035450
First received: December 16, 2009
Last updated: December 9, 2015
Last verified: December 2015
December 16, 2009
December 9, 2015
February 2010
March 2014   (Final data collection date for primary outcome measure)
  • target-lesion revascularization [ Time Frame: 1-year ]
  • all-cause death or myocardial infarction [ Time Frame: 3-year ]
Same as current
Complete list of historical versions of study NCT01035450 on ClinicalTrials.gov Archive Site
  • all-cause death [ Time Frame: 3-year ]
  • cardiac death [ Time Frame: 3-year ]
  • myocardial infarction [ Time Frame: 3-year ]
  • stent thrombosis (Academic Research Consortium definition) [ Time Frame: 3-year ]
  • ischemic and hemorrhagic strokes excluding transient ischemic attacks and secondary causes [ Time Frame: 3-year ]
  • bleeding complications (GUSTO and TIMI definition) [ Time Frame: 3-year ]
  • stent deployment success [ Time Frame: at implantation ]
  • procedure time [ Time Frame: at implantation ]
  • clinically-driven target-lesion revascularization [ Time Frame: 3-year ]
  • non-target-lesion revascularization [ Time Frame: 3-year ]
  • coronary artery bypass grafting [ Time Frame: 3-year ]
  • target-vessel revascularization [ Time Frame: 3-year ]
  • any repeat coronary revascularization [ Time Frame: 3-year ]
  • composite of cardiac death, myocardial infarction in the territory of the target vessel or target-lesion revascularization [ Time Frame: 3-year ]
  • composite of all-cause death, any myocardial infarction or any repeat coronary revascularization [ Time Frame: 3-year ]
Same as current
Not Provided
Not Provided
 
Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial
Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial
The purpose of this study is to evaluate whether the newly-approved everolimus-eluting stent is not inferior to the sirolimus-eluting stent in terms of the rate of target-lesion revascularization at 1-year and death or myocardial infarction at 3-year after stent implantation in the real world clinical practice.
Sirolimus-eluting stent is the most widely used coronary drug-eluting stent in Japan. Everolimus-eluting stent is a new coronary drug-eluting stent, which is going to be approved in the first quarter of 2010 by the Japanese Ministry of Health, Labor and Welfare. It has recently been reported that everolimus-eluting stent had lower rate of target-lesion revascularization and stent thrombosis at 1 year as compared with paclitaxel-eluting stent. However, trial results comparing everolimus-eluting stent with sirolimus-eluting stent are largely unknown. The purpose of this study is to evaluate whether the newly-approved everolimus-eluting stent is not inferior to the sirolimus-eluting stent in terms of the rate of target-lesion revascularization at 1-year and death or myocardial infarction at 3-year after stent implantation in the real world clinical practice. The design of this study is all-comer design enrolling patients scheduled for percutaneous coronary intervention using drug-eluting stents without any exclusion criteria.
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Coronary Artery Disease
  • Device: Everolimus-eluting stent
    Everolimus-eluting stent
  • Device: Sirolimus-eluting stent
    Sirolimus-eluting stent
  • Experimental: Everolimus-eluting stent
    Intervention: Device: Everolimus-eluting stent
  • Active Comparator: Sirolimus-eluting stent
    Intervention: Device: Sirolimus-eluting stent

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3206
May 2014
March 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients scheduled for percutaneous coronary intervention using drug-eluting stents

Exclusion Criteria:

Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT01035450
C338
Yes
Not Provided
Not Provided
Takeshi Morimoto, Kyoto University, Graduate School of Medicine
Takeshi Morimoto
Not Provided
Principal Investigator: Takeshi Kimura, MD Professor of Medicine, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
Kyoto University, Graduate School of Medicine
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP